News Sentiment

IRWD sentiment intelligence

Ironwood Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 57 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Drug Manufacturers - Specialty & Generic Read-through group
Latest close 3.54 Week of 19 Jun 2026
Weighted tone 52/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

79/100 classification confidence.

Company focus 57

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-3.0% over one week, -9.7% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Ironwood Pharmaceuticals (IRWD) adds 10M shares to 2019 equity incentive plan

Market Reaction

Balanced read

60/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 79/100 classification
One-week reaction -3.0% Price reacting lower
Trend fit Trend inactive -9.7% over four weeks
Fair value -32.8% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 9
Neutral 45
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 57
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 26
Market source 4
AD HOC NEWS 4
simplywall.st 3
Business Wire 2
MT Newswires 2
FinancialContent 2
Seeking Alpha 2

Event Lens

What the news is about

Classified themes
Market update 31
Earnings 12
Deals and strategy 5
Guidance 3
Regulatory and legal 2
Balance sheet 2
Capital return 1
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 57
Stock Titan Direct company coverage

Ironwood Pharmaceuticals (IRWD) adds 10M shares to 2019 equity incentive plan

Ironwood Pharmaceuticals (IRWD) announced that its stockholders approved an amendment to the 2019 Equity Incentive Plan, adding 10 million shares of Class A common stock for future equity-based compensation. This approval occurred at the 2026 Annual Meeting of Stockholders, where

Tone
Neutral 50/100
Event
Regulatory and legal
Published
18 Jun 2026 20:14
Source
Stock Titan
Stock Titan Direct company coverage

Ironwood (IRWD) director Marla Kessler receives 63,481-share restricted stock grant

Ironwood Pharmaceuticals director Marla L. Kessler was granted 63,481 shares of Class A Common Stock as restricted stock. This award was part of the company’s non-employee director compensation policy and vests in full before the next annual stockholders' meeting. Following this

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 21:09
Source
Stock Titan
Stock Titan Direct company coverage

Ironwood Pharmaceuticals (IRWD) director granted 63,481 restricted shares in latest Form 4

Ironwood Pharmaceuticals director Jon R. Duane was granted 63,481 shares of Class A Common Stock as equity compensation, as disclosed in a recent Form 4 filing. These restricted shares, awarded at $0.00, will vest fully on the day before the next annual stockholders' meeting, inc

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 21:09
Source
Stock Titan
Stock Titan Direct company coverage

Ironwood (NASDAQ: IRWD) director awarded restricted stock that vests before next meeting

Ironwood Pharmaceuticals director Alexander J. Denner was awarded restricted Class A Common Stock as non-cash compensation, with two grants on June 15 and June 16, 2026, totaling 67,546 shares. These shares were issued under the company's Non-employee Director Compensation Policy

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 21:09
Source
Stock Titan
Stock Titan Direct company coverage

Ironwood (NASDAQ: IRWD) director sells shares and receives new stock grant

Ironwood Pharmaceuticals Inc. director Julie McHugh reported both a sale and a grant of Class A Common Stock. She sold 21,571 shares at a weighted average price of $3.73 under a pre-arranged Rule 10b5-1 trading plan and received a grant of 63,481 restricted shares. After these tr

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 21:09
Source
Stock Titan
Stock Titan Direct company coverage

Ironwood Pharmaceuticals (IRWD) director receives 63,481-share grant

Ironwood Pharmaceuticals director Mark G. Currie was granted 63,481 shares of Class A common stock as restricted stock, awarded at no cash cost as part of his director compensation. Following this award, Currie directly holds 676,900 shares of Ironwood common stock. The restricte

Tone
Neutral 50/100
Event
Balance sheet
Published
17 Jun 2026 21:09
Source
Stock Titan
Stock Titan Direct company coverage

Ironwood Pharmaceuticals (IRWD) sets interim CFO fee and RSU grant

Ironwood Pharmaceuticals (IRWD) has amended a prior report to detail the compensation for Ronald Silver in his new role as interim chief financial officer. He will receive a monthly interim assignment fee of $12,250 and was granted 25,000 restricted stock units (RSUs) on May 19,

Tone
Neutral 50/100
Event
Market update
Published
21 May 2026 20:39
Source
Stock Titan
Stock Titan Direct company coverage

Ironwood (IRWD) PFO Ronald Silver receives 25,000-share restricted stock grant

Ronald Silver, PFO & PAO of Ironwood Pharmaceuticals Inc. (IRWD), has been granted 25,000 shares of restricted common stock as equity compensation. This award, valued at $0.00 per share, vests in two equal installments on each approximate anniversary of the grant date. Following

Tone
Neutral 50/100
Event
Market update
Published
21 May 2026 20:12
Source
Stock Titan
Business Wire Direct company coverage

Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026

Ironwood Pharmaceuticals will present data from its LANDMARK survey at Digestive Disease Week® 2026, focusing on healthcare professionals' insights into the burden of total parenteral nutrition for short bowel syndrome patients. The company will also share long-term safety and to

Tone
Positive 65/100
Event
Market update
Published
17 May 2026 07:39
Source
Business Wire
Stock Titan Direct company coverage

Armistice reports 15.03M Ironwood stake (NASDAQ: IRWD) in 13G/A

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 15,028,000 shares of Ironwood Pharmaceuticals (NASDAQ: IRWD) Class A common stock, representing 9.22% of the class, as detailed in an Amendment No. 6 to a Schedule 13G filing. Armistice Capital acts as t

Tone
Neutral 50/100
Event
Deals and strategy
Published
15 May 2026 15:39
Source
Stock Titan
FinancialContent Direct company coverage

Ironwood Pharmaceuticals, Inc. - Class A Common Stock (NQ: IRWD

This article provides recent news and financial updates for Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), including its stock performance. It compiles various news headlines from May to July 2021, covering topics like investor update calls, clinical trial results, business agree

Tone
Neutral 50/100
Event
Earnings
Published
15 May 2026 04:39
Source
FinancialContent
Stock Titan Direct company coverage

Renaissance reports 4.90% stake in Ironwood (IRWD)

Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation have reported a 4.90% beneficial stake in Ironwood Pharmaceuticals Inc. This stake amounts to 8,061,073 shares of Class A common stock, with both entities holding sole voting and sole dispositive power

Tone
Neutral 50/100
Event
Deals and strategy
Published
14 May 2026 21:10
Source
Stock Titan
FinancialContent Direct company coverage

Ironwood Pharmaceuticals, Inc. - Class A Common Stock (NQ: IRWD)

This page provides recent news and press releases for Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), highlighting financial results, conference participation, and updates on their therapies and pipeline. Key announcements include strong quarterly results, maintenance of financial

Tone
Positive 74/100
Event
Earnings
Published
14 May 2026 19:10
Source
FinancialContent
Stock Titan Direct company coverage

[8-K] IRONWOOD PHARMACEUTICALS INC Reports Material Event

Ironwood Pharmaceuticals (IRWD) announced that its Senior Vice President and Chief Financial Officer, Gregory Martini, will resign effective May 15, 2026. The company stated this resignation is unrelated to any disagreement concerning its financial reporting. Ronald Silver, curre

Tone
Neutral 50/100
Event
Market update
Published
13 May 2026 11:39
Source
Stock Titan